Indexed logomarkindexed.vc

Q32 Bio

IPO

Building the future of targeted immune therapeutics

Public · United States

Healthcare
Employees
11–50
Business Model
B2B
Website
q32bio.com
Last Round
Series BDec 2020
Rounds
2
Type
Public

About

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of both the innate and adaptive immune systems with the goal of re-balancing immunity. The company is focused on discovering and developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Q32 Bio's lead product candidate, bempikibart (ADX-914), is a fully human anti-IL-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The company is headquartered in Waltham, Massachusetts and trades on NASDAQ under the ticker QTTB.

Summary

Q32 Bio is a Healthcare company based in United States. Its most recent funding was a Series B round in Dec 2020. Investors include OrbiMed, Atlas Venture and Abingworth Bioventures.

LinkedInX (Twitter)

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Post-IPO EquityConcurrent Private PlacementMar 2024
$42.0M

Sign up to see all 4 rounds

Series A through Merger — per-round amounts, valuations, and who invested in each round.

Investors

OrbiMed

Lead

3 rounds

Atlas Venture

Lead

3 rounds

Abingworth Bioventures

3 rounds

Sanofi Ventures

3 rounds

Acorn Bioventures

2 rounds

Osage University Partners

2 rounds

CU Healthcare Innovation Fund

2 rounds

Children's Hospital Colorado Center for Innovation

2 rounds

Bristol Myers Squibb

1 round

Agent Capital

1 round

Similar Companies

MedlineIPO

Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...

Northfield, United States10001+Healthcare
Private Equity·$34.0B·Jan 2021
MultiPlanIPO

Healthcare cost management company providing data analytics and network-based payment solutions t...

New York, United States1001–5000Healthcare
Private Equity·$7.4B·Mar 2014
The Bountiful CompanyAcquired

American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...

Ronkonkoma, United States1001–5000Healthcare, Retail
Private Equity·$7.0B·Jul 2017
OneOncologyAcquired

OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...

Nashville, United States1001–5000Healthcare, Data & Analytics
Extension Round·$5.1B·Dec 2025
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth Equity·$5.1B·Aug 2022
Canopy Growth Corporation Common SharesIPO

World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...

Smiths Falls, Canada1001–5000Healthcare
Corporate Round·$4.5B·Jan 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Q32 Bio on Indexed.vc
<a href="https://indexed.vc/companies/q32-bio"><img src="https://indexed.vc/api/badge/company/q32-bio" alt="Q32 Bio on Indexed.vc" width="260" height="76" /></a>